{"id":128509,"name":"KANEKA PHARMA AMERICA, LLC","slug":"kaneka-pharma-america-llc","state":"CA","country":"United States of America","description":"Distributor of life science systems","totalSpending":1550000,"filings":35,"yearlySpending":[{"year":2018,"income":320000},{"year":2019,"income":300000},{"year":2020,"income":220000},{"year":2021,"income":190000},{"year":2022,"income":140000},{"year":2023,"income":120000},{"year":2024,"income":120000},{"year":2025,"income":140000}],"issues":[{"code":"MMM","display":"Medicare/Medicaid"}],"firms":["KING & SPALDING LLP"],"lobbyists":["ALLISON KASSIR","PREEYA PINTO","DAVID FARBER","WILLIAM CLARKSON","JEANNINE BENDER","MICHAEL ANDREWS","ALEXANDER (\"ANDER\") CRENSHAW","SCOTT DZIENGELSKI"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Centers For Medicare and Medicaid Services (CMS)","Health & Human Services, Dept of (HHS)"],"sampleDescriptions":["Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment","Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment","Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment","Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment","Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment"]}